Toshihiko Shiraiwa

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 182 citations

Diabetes Management, Cardiovascular Disease, Medicine +8

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

Tomoya Mita, Naoto Katakami, Hidenori Yoshii et al. · Diabetes Care · 2015 · 162 citations

Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation

Takeshi Miyatsuka, Hideaki Kaneto, Toshihiko Shiraiwa et al. · Genes & Development · 2006 · 154 citations · Full text

Persistent Expression, Transcriptional Regulation, Lineage Plasticity +12

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE)

Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa et al. · Diabetes Care · 2016 · 139 citations

Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients

Toshihiko Shiraiwa, Hideaki Kaneto, Takeshi Miyatsuka et al. · Biochemical and Biophysical Research Communications · 2005 · 104 citations

Metabolic Syndrome, Diabetic Retinopathy, Post-prandial Hyperglycemia +11